AstraZeneca Docket No. Z40323-3P US

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-26 (canceled)

Claim 27 (currently amended): A <u>non-solvated</u>, solid (S)-4-[[3-(dimethylamino)ethyl]-IIIindol-5-yl]-methyl}-2-oxazolidinoneeompound prepared by a process comprising:

- a) dissolving crude (S)-4-{[3-(dimethylamino)ethyl]-1H-indol-5-yl]-methyl}-2-oxazolidinone in a refluxing mixture of ethanol in ethyl acetate and filtering the hot solution;
- b) slowly cooling the filtered solution to a temperature of about 5°C;
- c) contrifuging the product from step b), washing with ethyl acetate then drying; and
- d) treating with acetone to remove solvated ethyl acetate.